Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

[Background] Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies.

Detalles Bibliográficos
Autores: Pérez de Llano, Luis A., Cosio, Borja G., Domingo, Christian, Urrutia, Isabel, Bobolea, Irina, Valero, Antonio, Entrenas Costa, Luis M., Quirce, Santiago, Barranco, Pilar, Malanda, Nuria Marina, Prieto Andrés, Luis, Álvarez Gutiérrez, Francisco Javier
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/213892
Acceso en línea:http://hdl.handle.net/10261/213892
Access Level:acceso abierto
Palabra clave:Asthma
Asthma management
Severe asthma
Omalizumab
Reslizumab
id ES_cbc09d52000760f5aa8b7e8d0f87fc7b
oai_identifier_str oai:digital.csic.es:10261/213892
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot StudyPérez de Llano, Luis A.Cosio, Borja G.Domingo, ChristianUrrutia, IsabelBobolea, IrinaValero, AntonioEntrenas Costa, Luis M.Quirce, SantiagoBarranco, PilarMalanda, Nuria MarinaPrieto Andrés, LuisÁlvarez Gutiérrez, Francisco JavierAsthmaAsthma managementSevere asthmaOmalizumabReslizumab[Background] Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies.[Objective] To evaluate the efficacy and safety of weight-based intravenous reslizumab dosing in patients who have previously failed therapy with omalizumab.[Methods] We carried out a 24-week prospective, multicenter, open-label, single-group, self-controlled study in patients with severe eosinophilic asthma who had previously failed to respond to omalizumab. The main objective was to determine whether treatment with reslizumab significantly improved asthma symptoms assessed by the Asthma Control Test (ACT) at week 24. Secondary objectives were to evaluate symptoms at weeks 4 and 12, change in FEV1 at week 24, and the incidence of severe exacerbations over the study period.[Results] Twenty-nine patients (62.1% women, median age, 50.8 years) were included in the study. The median ACT score significantly increased from 13.0 (interquartile range, 8.0-18.0) at baseline to 21.0 (interquartile range, 14.0-24.0) at 24 weeks (P = .002). Only 2 of 29 patients developed at least 1 severe exacerbation during follow-up and none of them required hospitalization. Overall, 15 of 25 patients (60%) were considered as being controlled (ACT score of ≥20 and no exacerbations) at week 24. The percentage of patients who were receiving daily systemic corticosteroids significantly decreased from 72.4% to 52.0% (P = .019). Adverse events were mostly moderate and within the range of previously reported side effects with reslizumab.[Conclusion] Reslizumab is an effective and safe option for patients with severe eosinophilic asthma and a history of omalizumab failure.ElsevierConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2020202020192020info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/213892reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.1016/j.jaip.2019.01.017Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2138922026-05-22T06:33:51Z
dc.title.none.fl_str_mv Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
title Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
spellingShingle Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
Pérez de Llano, Luis A.
Asthma
Asthma management
Severe asthma
Omalizumab
Reslizumab
title_short Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
title_full Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
title_fullStr Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
title_full_unstemmed Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
title_sort Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
dc.creator.none.fl_str_mv Pérez de Llano, Luis A.
Cosio, Borja G.
Domingo, Christian
Urrutia, Isabel
Bobolea, Irina
Valero, Antonio
Entrenas Costa, Luis M.
Quirce, Santiago
Barranco, Pilar
Malanda, Nuria Marina
Prieto Andrés, Luis
Álvarez Gutiérrez, Francisco Javier
author Pérez de Llano, Luis A.
author_facet Pérez de Llano, Luis A.
Cosio, Borja G.
Domingo, Christian
Urrutia, Isabel
Bobolea, Irina
Valero, Antonio
Entrenas Costa, Luis M.
Quirce, Santiago
Barranco, Pilar
Malanda, Nuria Marina
Prieto Andrés, Luis
Álvarez Gutiérrez, Francisco Javier
author_role author
author2 Cosio, Borja G.
Domingo, Christian
Urrutia, Isabel
Bobolea, Irina
Valero, Antonio
Entrenas Costa, Luis M.
Quirce, Santiago
Barranco, Pilar
Malanda, Nuria Marina
Prieto Andrés, Luis
Álvarez Gutiérrez, Francisco Javier
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Asthma
Asthma management
Severe asthma
Omalizumab
Reslizumab
topic Asthma
Asthma management
Severe asthma
Omalizumab
Reslizumab
description [Background] Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/213892
url http://hdl.handle.net/10261/213892
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://dx.doi.org/10.1016/j.jaip.2019.01.017
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419615742853120
score 15,812455

Similares en LA Referencia